Neumora Therapeutics operates as a clinical-stage biotechnology company.
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 11, 2022 | Series B | $112M | 10 | Mubadala Capital Ventures | — | Detail |
Oct 7, 2021 | Series A | $400M | 14 | ARCH Venture Partners | — | Detail |
Oct 7, 2021 | Corporate Round | $100M | 1 | Amgen | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Mubadala Capital Ventures | Yes | Series B |
ARCH Venture Partners | — | Series B |
Abu Dhabi Growth Fund | — | Series B |
Altitude Life Science Ventures | — | Series B |
Amgen | — | Series B |
EXOR N.V. | — | Series B |
F-Prime Capital | — | Series B |
Invus | — | Series B |
Newpath Management | — | Series B |
Polaris Partners | — | Series B |